IDS and mucopolysaccharidosis type 2: These data, along with those from the primary study [14], support the benefits of early initiation of ERT in patients with MPS II; further evidence for this approach includes preclinical and clinical evidence with IV idursulfase and real-world outcomes data, plus case reports of siblings facilitating comparisons of early versus delayed treatment [16–18].